How long will investors still hold out patience for Nike after two years of a “stale innovation pipeline?”
Analyst lifts price target on Oncolytics with new clarity from the FDA on Reolysin’s path forward to approval.
One top analyst raises price target on Oracle; another analyst believes the worst is now over for the giant.
However, Aurinia’s not-so-secret lead drug asset Voclosporin offers a compelling partnering opportunity.
AMD has good odds for reward; Nvidia’s GPU game is strong; but Intel’s PC segment is the real gamble.
Synergy protects “financial health” without the sacrifice of extra pressure on share price, says Canaccord.